he results of clinical trials can be presented in many ways. These results will often benefit by trmlslation into a more memlingful form appropriate for making clinical decisions for individual patients. The purpose of this article is to present some concepts that can help clinicians make such translations, For our first illustration, consider a 52 year old woman who consults you about the need for mammographic screening. She has no family history of breast cancer and has never had a breast mass. Both her parents died in their fifties of heart disease. She has been told to have yearly mammograms, but she is frankly more concerned about her heart. What can you tell her? making them seem more important than they are. For you and your patients, the relative rate reduction is meaningless without reference to the underlying rate because, without it, the absolute change in risk is unknown.
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DO NOT BE FOOLED BY RELATIVE CHANGES
Let us look at the published overview of Swedish mammographic screening studies. Nystrom et al. reported a 30% decrease in the breast cance~specific mortality rate for screened women versus control women. ~ This sounds impressive, I suspect that if you told your patient that she must have mammograms because they will re duce her risk of dying of breast cancer by 30%. she would relent, However. the authors are reporting a relative rate rednctiork which means that whatever the mortality rate experienced by the control women, the mortality rate for the screened women was 70% of it (i.e.. 30% lower thin1 100% How can one tell whether an author is reporting rein tire or absolute chmlges? The distinction caw be subtle, with a relative change being indicated by a percentage re duction and an absolute change by a percentage difference. However, most authors are kind enough to use more specific terminology. A relative risk. usually expressed as a decimal fraction rather than as a percentage, is the proper term to indicate a relative rate reduction (it is actually its complement, i,e,. 1 minus the relative rate reduction--in our example, the 30% rate reduction is the same as a rela tire risk of 0.7), Attributable cisk refers to an absolute difference. Some authors make it even easier by reporting actual rates for each group and then calculating the rela tire risk or the absolute difference between them or both (the term attributable risk is less often used), When authors leave out this information, as Nystrom et al. did, it is importmK to make the calculations oneself. showed a reduction in the median duration of posther petic neuralgia from about 4 months in placebo-treated patients to about 2 months in the famciclovir treated pm tients. In a single sentence, however, the authors state: "No benefit was seen for patients younger than 50 years," As about half the patients were younger than 50, this is an important subgroup to analyze. It deserves more space thin1 it was given by authors, who did not even mention it in the abstract. What if the authors had failed to mention it at all? How would we know to look for the information?
LOOK FOR CLINICALLY IMPORTANT SUBGROUPS
Authors (as well as readers) should always consider those variables that might affect the outcome in either treated or untreated patients. They should report results separately for clinically importmlt subgroups of patients who might be expected to have different prognoses. It is common for a treatment that is effective for patients with a poor prognosis to be ineffective for those with a good prognosis. This should be apparent from the discussion above about relative rates. If the relative effectiveness of the treatment is the same regardless of prognosis, the ab solute difference in outcome will be less for patients whose underlying risk is lower. The treatment will be less important to patients with better prognoses. Trying et al.
concede: "~i'he incidence of postherpetic neuralgia in creases sharply with increasing age." Their decision to study so many young patients may therefore be questioned. Having studied them, they should have planned to analyze their results separately for different age groups. It is extremely important to note that it is not sufficient for authors to report that certain subgroups were analyzed, but the results were not significantly different from each other (sometimes referred to as a test for ~wter ogeneity). Authors may even report the results of such tests without indicating that they used p values to obtain them (which must always be the case). The use ofp values for this purpose is inappropriate. Although a positive test (p value < .05) indicates that the degree of variation is not likely due to chmlce, it does not tell us how clinically important it is: certainly a negative test, with a p value > .05, gives no assurance that it is unimportant.
We need to know how d~fferent the results were for young patients compared with older ones. The p value alone cannot answer this question because it depends not only on the magnitude of differences, but also on the number of patients in each subgroup.: If we break a study into small enough subgroups, we can be assured of finding no statistically significant differences among them. Negative tests based on p values cannot help us interpret study results. Rather, results for each subgroup must be pre sented so that differences can be contrasted, P values may be appropriately used to compare treatment and control patients within each subgroup. However, confi dence intervals will better indicate how much precision can be associated with the results. 4
What about our patient? Certainly, Trying et al. give us no support for the use of fmnciclovir in this particular individual because he falls into the group of younger pa tients who showed no benefit from treatment. But what if his birthday is tomorrow?., Should we wait 1 day and then give him treatment? Clearly, there is something intuitively wrong with this dichotomy between patients who are older or younger than 50 years of age. How do we handle the patient who falls on the cutoff? What about patients near the cutoff?., Must we limit our treatment on the basis of arbitrary decisions by trialists?
I NTE RPR ET CUTPOI NTS CAUTIOUSLY
The problem here is that age, like most biological variables, is continuous, i.e., it may take on any value within a range, including fractions. Yet. for statistical purposes this variable was dichtomized, so that patients were separated into only two groups, older or younger than 50 years of age. This lumping, as it were, may sometimes be necessary to allow for large enough groups to make statistical analysis possible. However, we must be careful how we interpret such analyses, Once we determine that age /s an important factor, we must recognize that our dichotomy is an artificial one.
The cutpoint, which was chosen for the purposes of statistical analysis, will rarely reflect the true relation be tween a variable and an outcome. Hence, our problem with the patient who falls exactly on the cutpoint. We know that risks do not change dramatically on a patient's birthday. One may Just as well toss a coin as refer to the dichotomized data to determine which prognostic group the patient belongs to the choice is arbitrary. We must be especially careful when cutpoints are chosen on the basis of sample data, as it can be shown that cutpoints determined after examination of the data may exaggerate observed relationships, especially when an "optimal" level is determined by repeated calculations, c' This concept has tremendous clinical importance. We frequently base treatment decisions on data involving con tinuous variables that have been artificially dichotomized. Unfortunately, we are rarely provided with any information beyond the original dichotomy. In the absence of such information, the clinician must interpret cutpoints Judiciously, remembering their limitations. We must make our best guess as to how a variable behaves, recognizing that good clinical Judgment is likely to be more reasonable than slavish adherence to an artificial cutpoint. We know that the risk of postherpetic neuralgia "increases sharply with increasing age." We suspect, then. that this 49-yearold has a moderate risk of postherpetic neuralgia, the duration of which might be somewhat reduced by famci clovir, A 39-year-old will probably get little benefit. whereas a 59 year old is likely to profit well. 
